Asa Petersen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/233350/publications.pdf

Version: 2024-02-01

79 papers	3,660 citations	147801 31 h-index	138484 58 g-index
84 all docs	84 docs citations	84 times ranked	3915 citing authors

#	Article	IF	Citations
1	IKKÎ² signaling mediates metabolic changes in the hypothalamus of a Huntington disease mouse model. IScience, 2022, 25, 103771.	4.1	3
2	Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice. Molecular Metabolism, 2022, 57, 101439.	6.5	11
3	Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. Parkinsonism and Related Disorders, 2022, 99, 23-29.	2.2	8
4	Brain white matter lesions are associated with reduced hypothalamic volume and cranial radiotherapy in childhoodâ€onset craniopharyngioma. Clinical Endocrinology, 2021, 94, 48-57.	2.4	3
5	Effects of mutant huntingtin inactivation on Huntington diseaseâ€related behaviours in the BACHD mouse model. Neuropathology and Applied Neurobiology, 2021, 47, 564-578.	3.2	1
6	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2021, 47, 979-989.	3.2	31
7	Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease. Heliyon, 2021, 7, e07808.	3.2	2
8	Early white matter pathology in the fornix of the limbic system in Huntington disease. Acta Neuropathologica, 2021, 142, 791-806.	7.7	13
9	A15â€...Hypothalamic expression of huntingtin causes distinct metabolic changes in the R6/2 and bachd mouse models of huntingtonâ€™s disease. , 2021, , .		0
10	Imbalance of the oxytocin-vasopressin system contributes to the neuropsychiatric phenotype in the BACHD mouse model of Huntington disease. Psychoneuroendocrinology, 2020, 119, 104773.	2.7	8
11	SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. Neuropathology and Applied Neurobiology, 2019, 45, 361-379.	3.2	31
12	The Role of Hypothalamic Pathology for Non-Motor Features of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2019, 8, 375-391.	1.9	29
13	The psychopharmacology of Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 179-189.	1.8	8
14	Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity. International Journal of Obesity, 2019, 43, 533-544.	3.4	19
15	Microstructural white matter alterations and hippocampal volumes are associated with cognitive deficits in craniopharyngioma. European Journal of Endocrinology, 2018, 178, 577-587.	3.7	24
16	Laminin Î±1 reduces muscular dystrophy in dy 2J mice. Matrix Biology, 2018, 70, 36-49.	3.6	19
17	Thermoregulatory disorders in Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 761-775.	1.8	6
18	Thermoregulation in amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 749-760.	1.8	7

#	Article	IF	Citations
19	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. ENeuro, 2018, 5, ENEURO.0234-18.2018.	1.9	10
20	mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntingtonâ€™s Disease. Molecular Cell, 2018, 71, 675-688.e6.	9.7	50
21	Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8765-E8774.	7.1	47
22	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. Frontiers in Molecular Neuroscience, 2018, 11, 2.	2.9	113
23	Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. Cell Reports, 2018, 24, 1397-1406.	6.4	66
24	Microstructure alterations in the hypothalamus in cranially radiated childhood leukaemia survivors but not in craniopharyngioma patients unaffected by hypothalamic damage. Clinical Endocrinology, 2017, 87, 359-366.	2.4	7
25	Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1033-1041.	1.9	113
26	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 2017, 97, 179-188.	4.4	40
27	Associations between Metabolic Risk Factors and the Hypothalamic Volume in Childhood Leukemia Survivors Treated with Cranial Radiotherapy. PLoS ONE, 2016, 11, e0147575.	2.5	14
28	Neuropeptide Y (<scp>NPY</scp>) in cerebrospinal fluid from patients with Huntington's Disease: increased <scp>NPY</scp> levels and differential degradation of the <scp>NPY</scp>_{1â€“30} fragment. Journal of Neurochemistry, 2016, 137, 820-837.	3.9	17
29	Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntingtonâ€™s disease. Scientific Reports, 2016, 6, 28322.	3.3	18
30	Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function. Journal of the Neurological Sciences, 2016, 364, 148-153.	0.6	29
31	Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue. Scientific Reports, 2015, 5, 14598.	3.3	16
32	Selective loss of oxytocin and vasopressin in the hypothalamus in early <scp>H</scp>untington disease: a case study. Neuropathology and Applied Neurobiology, 2015, 41, 843-848.	3.2	31
33	Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study. PLoS ONE, 2015, 10, e0117593.	2.5	30
34	Analysis of Nonmotor Features in Murine Models of Huntington Disease. , 2015, , 583-602.		6
35	Low dietary protein content alleviates motor symptoms in mice with mutant dynactin/dynein-mediated neurodegeneration. Human Molecular Genetics, 2015, 24, 2228-2240.	2.9	22
36	Effects of Deletion of Mutant Huntingtin in Steroidogenic Factor 1 Neurons on the Psychiatric and Metabolic Phenotype in the BACHD Mouse Model of Huntington Disease. PLoS ONE, 2014, 9, e107691.	2.5	16

#	Article	IF	Citations
37	Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Human Molecular Genetics, 2013, 22, 3485-3497.	2.9	67
38	Maintenance of Basal Levels of Autophagy in Huntingtonâ€™s Disease Mouse Models Displaying Metabolic Dysfunction. PLoS ONE, 2013, 8, e83050.	2.5	21
39	Hypothalamic and Limbic System Changes in Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 5-16.	1.9	41
40	F01â€…Establishment of novel assays for quantification of full-length wild-type and mutant huntingtin by using the alphalisa technology. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A21.2-A21.	1.9	0
41	Characterization of a rat model of Huntingtonâ€™s disease based on targeted expression of mutant huntingtin in the forebrain using adenoâ€associated viral vectors. European Journal of Neuroscience, 2012, 36, 2789-2800.	2.6	11
42	Expression of Mutant Huntingtin in Leptin Receptor-Expressing Neurons Does Not Control the Metabolic and Psychiatric Phenotype of the BACHD Mouse. PLoS ONE, 2012, 7, e51168.	2.5	18
43	Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits. Cell Metabolism, 2011, 13, 428-439.	16.2	90
44	Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides, 2011, 45, 401-406.	2.2	59
45	Eating and hypothalamus changes in behavioralâ€variant frontotemporal dementia. Annals of Neurology, 2011, 69, 312-319.	5.3	158
46	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica, 2010, 120, 777-788.	7.7	93
47	Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease, 2010, 40, 531-543.	4.4	74
48	Transthyretin as a potential CSF biomarker for Alzheimerâ€™s disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. European Journal of Neurology, 2010, 17, 456-460.	3.3	22
49	F05â€…The experience of a genetic brain disorder: cultural and social perspectives on huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A24.1-A24.	1.9	0
50	Hypothalamic and Neuroendocrine Changes in Huntingtons Disease. Current Drug Targets, 2010, 11, 1237-1249.	2.1	41
51	Huntingtonâ€™s Disease â€“ New Perspectives Based on Neuroendocrine Changes in Rodent Models. Neurodegenerative Diseases, 2009, 6, 154-164.	1.4	25
52	Increased levels of cocaine and amphetamine regulated transcript in two animal models of depression and anxiety. Neurobiology of Disease, 2009, 34, 375-380.	4.4	32
53	Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. Journal of Affective Disorders, 2009, 113, 179-182.	4.1	61
54	Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic Î±2-receptor levels in a transgenic Huntington's disease rat model. Behavioural Brain Research, 2009, 205, 175-182.	2.2	35

#	Article	IF	Citations
55	Nortriptyline mediates behavioral effects without affecting hippocampal cytogenesis in a genetic rat depression model. Neuroscience Letters, 2009, 451, 148-151.	2.1	21
56	Reduced CSF CART in dementia with Lewy bodies. Neuroscience Letters, 2009, 453, 104-106.	2.1	26
57	Islet Î²-cell area and hormone expression are unaltered in Huntingtonâ€™s disease. Histochemistry and Cell Biology, 2008, 129, 623-629.	1.7	24
58	Transthyretin in cerebrospinal fluid from suicide attempters. Journal of Affective Disorders, 2008, 109, 205-208.	4.1	6
59	Increased metabolism in the R6/2 mouse model of Huntingtonâ€™s disease. Neurobiology of Disease, 2008, 29, 41-51.	4.4	114
60	Escitalopram reduces increased hippocampal cytogenesis in a genetic rat depression model. Neuroscience Letters, 2008, 436, 305-308.	2.1	24
61	Cocaine and amphetamine regulated transcript (CART) in suicide attempters. Psychiatry Research, 2008, 158, 117-122.	3.3	7
62	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Research Bulletin, 2008, 76, 70-79.	3.0	82
63	Sex differences in a transgenic rat model of Huntington's disease: decreased 17Î²-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Human Molecular Genetics, 2008, 17, 2595-2609.	2.9	114
64	Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 2008, 132, 919-932.	7.6	135
65	Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology, 2007, 17, 573-579.	0.7	176
66	Cocaineâ€•and amphetamineâ€•regulated transcript is increased in Huntington disease. Movement Disorders, 2007, 22, 1952-1954.	3.9	18
67	Testicular degeneration in Huntington disease. Neurobiology of Disease, 2007, 26, 512-520.	4.4	90
68	Cerebrospinal fluid levels of orexinâ€A are not a clinically useful biomarker for Huntington disease. Clinical Genetics, 2006, 70, 78-79.	2.0	31
69	Hypothalamicâ€“endocrine aspects in Huntington's disease. European Journal of Neuroscience, 2006, 24, 961-967.	2.6	167
70	Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Human Molecular Genetics, 2006, 15, 1713-1721.	2.9	122
71	Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. European Journal of Neuroscience, 2005, 22, 1541-1546.	2.6	61
72	Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice. BMC Cell Biology, 2005, 6, 34.	3.0	8

#	Article	IF	Citations
73	The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient Î²-cell mass and exocytosis. Human Molecular Genetics, 2005, 14, 565-574.	2.9	129
74	Orexin loss in Huntington's disease. Human Molecular Genetics, 2005, 14, 39-47.	2.9	246
75	Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiology of Disease, 2005, 20, 744-751.	4.4	158
76	Huntington's disease: The mystery unfolds?. International Review of Neurobiology, 2002, 53, 315-339.	2.0	12
77	Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease. Experimental Neurology, 2002, 175, 297-300.	4.1	47
78	Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice. Neurobiology of Disease, 2002, 11, 134-146.	4.4	86
79	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. European Journal of Neuroscience, 2001, 14, 1425-1435.	2.6	39